SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Multiple myeloma (MM)	Glycogen synthase kinase 3β (GSK3B); NF-κB; nuclear factor of κ light polypeptide gene enhancer in B cells 2 p49/p100 (NFKB2; p52)	*In vitro* and mouse studies suggest inhibiting GSK3B could help treat a subset of MM with constitutively active NF-κB signaling. In mice with an MM cell line that had an activated NF-κB pathway, transplantation of cells expressing a mutant form of the NF-κB-inhibitory protein NFKB2 decreased tumor growth compared with transplantation of cells expressing wild-type NFKB2. In the MM cell line, inhibitors of GSK3B, which phosphorylates NFKB2, decreased both NF-κB signaling and cell viability compared with vehicle. Next steps include testing GSK3B inhibitors in animal models of MM. DiaMedica Inc.'s GSK3B inhibitor DM-99 is in Phase II testing to treat diabetes. Neurim Pharmaceuticals Ltd.'s Neu-120, a GSK3B inhibitor, is in Phase II testing to treat Parkinson's disease (PD). *SciBX* 5(11); doi:10.1038/scibx.2012.279 Published online March 15, 2012	Unpatented; an anti–phospho-NFKB2 antibody that can measure the efficacy of GSK3B inhibition is available for licensing	Busino, L. *et al. Nat. Cell Biol.*; published online March 4, 2012; doi:10.1038/ncb2463 **Contact:** Michele Pagano, NYU Cancer Institute, New York University Langone Medical Center, New York, N.Y. e-mail: michele.pagano@nyumc.org